Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
GSK has recovered a fraction of its recent losses, up 1.4% on Wednesday to 1790.5p, but the week is still negative and the three weeks before October 28 earnings leave the stock sitting 3% lower on the month, still the clear laggard in European pharma.
The borrow market remains irrelevant to the thesis here. Availability is effectively unlimited, with over 1.6 billion shares available and borrowing costs holding at a negligible 0.58%. Short sellers have not pressed the stock with any conviction, and the ORTEX short score has actually ticked higher this week, rising from 34.2 at the end of September to 38.9 now, though that still places it in a broadly neutral zone. For context, the previous note a week ago flagged the short score easing toward 34: it has since moved back up, driven by a combination of price softness and modest lending-market activity, but nothing in the data points to aggressive directional positioning from the short side.
The more interesting divergence is in how GSK's peers are trading relative to it. AZN fell 0.8% on the week, roughly in line with GSK, but NOVN was flat, HLN added 1.4%, and Roper Technologies on the SWX gained 3.1%. At the other end, BAYN dropped 8.3%, which makes GSK's week look less isolated, but the year-to-date underperformance remains the defining context. This is not a week where a broader sector sell-off is dragging GSK down; it is continuing to underperform on its own.
The analyst consensus has not shifted. The mean price target is 2172.9p against a current price of 1790.5p, implying around 21% upside. That gap is large enough to be the single most notable feature of the Street's view: either the consensus is right and the stock is materially cheap, or the targets have not fully adjusted to persistent litigation headwinds and a pipeline that has disappointed relative to AstraZeneca. Factor scores add colour here: the analyst recommendation differential ranks in the 92nd percentile, meaning GSK's buy-to-sell ratio is unusually skewed toward buys relative to the broader universe. The dividend score ranks 90th percentile. But EPS surprise ranks in only the 13th percentile, a low reading that suggests the company has been consistently missing estimates, which helps explain why the consensus target has so far not translated into price momentum.
Insider activity from September is worth noting, though not for the size of the trades. The Non-Executive Chair Sir Jonathan Symonds bought 1,500 shares at 1881.1p on September 18, and independent director Roy Jackobs added 936 shares the same day. Neither trade is large in absolute terms, and both carry low significance scores. A cluster of much smaller share-scheme purchases also appeared on September 9 across several senior executives. Taken together the net insider position over the past 90 days is a modest 2,609 shares on the buy side. The signal is faint, but the direction is consistent: no insider selling at these levels.
The last time GSK reported, on July 29, the stock fell 4.4% on the day and was down 5.6% by the end of the following week. The print before that, in late July, produced a 2.3% gain on the day but a 2.4% loss over five days. The pattern suggests the market has been willing to sell into any relief rally. With three weeks to October 28, the question is whether the 21% implied upside to consensus targets begins to attract buyers ahead of the release, or whether the litigation uncertainty and recent EPS disappointment keep the stock range-bound.
See the live data behind this article on ORTEX.
Open GSK on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
